These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Targeted magnetic resonance imaging with intraperitoneal and intravenous streptavidin (SA)-DTPA-Gd: a comparative study in tumor-bearing nude mice.
    Author: Ye J, Xu YK, Liu X, Lü GS.
    Journal: Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):139-43. PubMed ID: 16503514.
    Abstract:
    OBJECTIVE: To investigate the effect of streptavidin (SA)-DTPA-Gd after intraperitoneal and intravenous administration for tumor enhancement in targeted magnetic resonance imaging (MRI). METHODS: Biotinylated monoclonal antibody CL3 (600 microg) was intravenously injected into 12 BALB/c nude mice with subcutaneous inoculation of LoVo cells, followed by administration of 80 microg avidin as the chaser 24 h later and then SA-DTPA-Gd was injected intravenously or intraperitoneally after another 30 min. MRI was performed before and 20, 60 min and 3, 6, 9, 12 h after the injection of the contrast agents, and the MR signal intensity of the tumor and liver was determined. RESULT: The maximum enhancement ratio of the tumor was 70.2% in the intravenous injection group and 46.4% in the intraperitoneal group, showing significant difference between them. The maximal enhancement rate of the liver was 23.7% in the intraperitoneal group and 20.4% in the intravenous group, showing no significant difference. CONCLUSION: MR targeted imaging with biotinylated monoclonal antibody CL3 and SA-DTPA-Gd has specific enhancement effect. Higher blood level of SA-DTPA-Gd in the intravenous group facilitates the tumor enhancement in MRI in subcutaneous tumor model.
    [Abstract] [Full Text] [Related] [New Search]